HROW vs PAHC vs AMRX vs PCRX

For growth investors, Harrow Health, Inc.

(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus 3. 6% for Pacira BioSciences, Inc. (PCRX). Phibro Animal Health Corporation (PAHC) offers the better valuation at 36. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Harrow Health, Inc. (HROW) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Phibro Animal Health Corporation (PAHC) is the cheapest at 36.

3x versus Pacira BioSciences, Inc. at 147. 8x. On forward P/E, Pacira BioSciences, Inc. is actually cheaper at 8. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Harrow Health, Inc.

(HROW) delivered a total return of +378. 0%, compared to -62. 6% for Pacira BioSciences, Inc. (PCRX). Over 10 years, the gap is even starker: HROW returned +914. 3% versus AMRX's -54. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pacira BioSciences, Inc.

(PCRX) is the lower-risk stock at 0. 47β versus Harrow Health, Inc. 's 2. 13β — meaning HROW is approximately 353% more volatile than PCRX relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Harrow Health, Inc.

(HROW) is pulling ahead at 36. 4% versus 3. 6% for Pacira BioSciences, Inc. (PCRX). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to 71. 4% for Harrow Health, Inc.. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Phibro Animal Health Corporation (PAHC) is the more profitable company, earning 3.

7% net margin versus -1. 9% for Harrow Health, Inc. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HROW leads at 11. 2% versus -0. 2% for AMRX. At the gross margin level — before operating expenses — PCRX leads at 79. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pacira BioSciences, Inc.

(PCRX) trades at 8. 6x forward P/E versus 82. 9x for Harrow Health, Inc. — 74. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HROW: 93. 8% to $75. 67.

In this comparison, PAHC (1.

1% yield) pays a dividend. HROW, AMRX, PCRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pacira BioSciences, Inc.

(PCRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Harrow Health, Inc. (HROW) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PCRX: -51. 2%, HROW: +914. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HROW is a small-cap high-growth stock; PAHC is a small-cap high-growth stock; AMRX is a small-cap quality compounder stock; PCRX is a small-cap quality compounder stock. PAHC pays a dividend while HROW, AMRX, PCRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.